"Promising Results: Pfizer and BioNTech's Combined COVID-Flu Vaccine Shows Strong Immune Response"
TL;DR
Pfizer and BioNTech have announced that their flu-COVID vaccine has generated a strong immune response against strains of both viruses in an early- to mid-stage trial. The companies plan to proceed with a late-stage trial in the coming months. The vaccine has the potential to simplify immunization practices by addressing two respiratory diseases with a single injection. The trial data showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains.
- Pfizer, BioNtech say flu-COVID shot generates strong immune response in trial KSL.com
- Pfizer and BioNTech report positive findings for COVID-flu mRNA combo vaccine University of Minnesota Twin Cities
- What an updated COVID vaccine will mean for Moderna Yahoo Finance
- Mixed Day for Vaccine Stocks as Terrible News Emerges - TipRanks.com TipRanks
- Combined COVID-flu vaccine from Pfizer, BioNTech moving to late-stage testing The Hill
Want the full story? Read the original reporting
Read on KSL.com